Division of Synektik SA
Spinoff of R&D activity to Syn2bio
Pursuant to the decision of the management board of Synektik SA dated 27 March 2025, a division of the company is planned through the transfer of a portion of the assets, in the form of an organized part of the enterprise, to a new entity, the company Syn2bio SA.
The following will be transferred to Syn2bio:
- Cardiotracer project – an innovative radiopharmaceutical for diagnosis of heart disease involving myocardial perfusion,
- Centre for Research on New Compounds – the unit engaged in the search for innovative new pharmaceutical compounds, their study (preclinical and clinical trials), registration, and preparation for market launch as medical devices.
Ultimately, the Syn2bio business will focus on:
- Conducting R&D work and commercialization of the cardiotracer,
- Seeking and developing new pharmaceutical compounds – from the research phase, through the registration process, to market launch of ready medicinal products.
Documents concerning the division
ESPI Report No. 23/2026 on the approval by the Registry Court of the division of Synektik SA, published on 30 March 2026 (English)
ESPI Report of Syn2bio SA No. 2/2026 on the fulfilment of the condition for the admission of Syn2bio SA shares to trading, published on 30 March 2026 (English)
ESPI Report of Syn2bio SA No. 1/2026 on the registration of the increase in the share capital of Syn2bio SA in connection with the division of Synektik S.A., published on 30 March 2026 (English)
ESPI Report 14/2026 on the second notification of intent to carry out a division of Synektik SA published on 18 February 2026 (English)
ESPI Report 12/2026 on the first notification of intent to carry out a division of Synektik SA published on 3 February 2026 (English)
ESPI Report 44/2025 on the auditor’s report on the audit of the Division Plan published on 3 September 2025 (English)
Division Plan published by Synektik and Syn2bio on 23 July 2025, updated on 2 September 2025 (Polish)
Auditor’s report on the audit of the Division Plan published on 2 September 2025 (Polish)
Division Plan published by Synektik and Syn2bio on 23 July 2025 (Polish)
Management Boards statement regarding the divison published on 23 July 2025 (Polish)
ESPI Report 37/2025 on agreeing and adoption of the division plan of Synektik SA published on 23 July 2025 (English)
ESPI Report 23/2025 on adoption of directional resolution on division of Synektik SA published on 27 March 2025 (English)
Press releases concerning the division
30 March 2026
The division of Synektik is complete – the court has registered
the issue of Syn2bio shares
19 March 2026
Synektik shareholders have unanimously approved the division of the company and spinoff of the cardiotracer project to Syn2bio
12 March 2026
KNF has approved the Syn2bio prospectus. The debut on the WSE is planned for April
17 November 2025
Synektik edges closer to demerger as Syn2bio files prospectus with KNF
23 July 2025
Synektik one step closer to planned division
27 March 2025
Synektik plans to divide. It is spinning off the cardiotracer research project into a new company which will also be listed on the WSE